Mitoxantrone

This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BZ114NVM5P, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but generally known as mitoxantrone, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules Mitoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG. The term MITOXANTRONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules mitoxantrone in its Anatomical Therapeutic Chemical (ATC) Classification. MITOXANTRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mitoxantrone under HS 29225000 and SITC 51467. As of Q4 2014, MITOXANTRONE remains the US FDA Preferred Term for this commodity. Mitoxantrone bears US NLM identifiers UMLS ID C0026259 and NCI Concept Code C62050. SMILES: O=C1C2C(C(NCCNCCO)CCC2NCCNCCO)C(=O)C2C1C(O)CCC2O.